On February 25, 2020 CytomX Therapeutics, Inc. (Nasdaq: CTMX), a clinical-stage oncology-focused biopharmaceutical company pioneering a novel class of investigational antibody therapeutics based on its Probody therapeutic technology platform, reported that Sean McCarthy, D.Phil., president, chief executive officer and chairman, will participate at Cowen and Company’s 40th Annual Health Care Conference in Boston, Massachusetts (Press release, CytomX Therapeutics, FEB 25, 2020, http://ir.cytomx.com/news-releases/news-release-details/cytomx-therapeutics-present-cowen-and-company-40th-annual-health [SID1234554723]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Date: Tuesday, March 3, 2020
Time: 10:00 a.m. E.T / 7:00 a.m. P.T.
Location: Boston, Massachusetts
A live audio of this webcast will be available through the "Investors & News" section of CytomX’s website. An archived replay will be available for 60 days following the event.